Browse the corpus

REFERENCES American Diabetes Association, “Standards of Medical Care in Diabetes Mellitus -- 2012,” Diabetes Care , 2012, 35(Suppl 1):11-63. [PubMed 22187469 ] Dackis CA and Gold MS, “Bromocriptine as Treatment of Cocaine Abuse,” Lancet , 1985, 1(8438):1151-2. de Groot AN, van Dongen PW, Vree TB, et al, “Ergot Alkaloids. Current Status and Review of Clinical Pharmacology and Therapeutic Use Compared With Other Oxytocics in Obstetrics and Gynaecology,” Drugs , 1998, 56(4):523-35. [PubMed 9806101 ] Factor SA, “Current Status of Symptomatic Medical Therapy in Parkinson’s Disease,” Neurotherapeutics , 2008, 5(2):164-80. [PubMed 18394561 ] Gaziano JM, Cincotta AH, O’Connor CM, et al, “Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes,” Diabetes Care , 2010, 33(7):1503-8. [PubMed 20332352 ] Gortney JS, Fagan A, and Kissack JC, “Neuroleptic Malignant Syndrome Secondary to Quetiapine,” Ann Pharmacother , 2009, 43(4):785-91. [PubMed 19299325 ] Handelsman Y, Mechanick JI, Blonde L, et al, “American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan,” Endocr Pract , 2011, 17(Suppl 2):1-53. [PubMed 21474420 ] Koller WC, Silver DE, and Lieberman A, “An Algorithm for the Management of Parkinson's Disease,” Neurology , 1994, 44(12 Suppl 10):1-52. [PubMed 8290041 ] Lejoyeux M, et al, “Serotonin Syndrome: Incidence, Symptoms, and Treatment,” CNS Drugs , 1994, 2:132-43. Melmed S and Braunstein GD, “Bromocriptine and Pleuropulmonary Disease,” Arch Intern Med , 1989, 149(2):258-9. [PubMed 2916870 ] Molina JA, Sàinz-Artiga MJ, Fraile A, et al, “Pathologic Gambling in Parkinson's Disease: A Behavioral Manifestation of Pharmacologic Treatment,” Mov Disord , 2000, 15(5):869-72. [PubMed 11009192 ] Molitch ME, “Management of Prolactinomas During Pregnancy,” J Reprod Med , 1999, 44(12 Suppl):1121-6. [PubMed 10649822 ] Morgans D, “Re: Parlodel,” Aust N Z J Obstet Gynaecol , 1995, 35(2):228-9. Parkes D, “Drug Therapy: Bromocriptine,” N Engl J Med , 1979, 301(16):873-8. [PubMed 384250 ] Pijl H, Ohashi S, Matsuda M, et al, “Bromocriptine: A Novel Approach to the Treatment of Type 2 Diabetes,” Diabetes Care , 2000, 23(8):1154-61. [PubMed 10937514 ]

Morgans D, “Re: Parlodel,” Aust N Z J Obstet Gynaecol , 1995, 35(2):228-9. Parkes D, “Drug Therapy: Bromocriptine,” N Engl J Med , 1979, 301(16):873-8. [PubMed 384250 ] Pijl H, Ohashi S, Matsuda M, et al, “Bromocriptine: A Novel Approach to the Treatment of Type 2 Diabetes,” Diabetes Care , 2000, 23(8):1154-61. [PubMed 10937514 ] Stern MB, “Contemporary Approaches to the Pharmacotherapeutic Management of Parkinson's Disease: An Overview,” Neurology , 1997, 49(1 Suppl 1):2-9. [PubMed 9222162 ] Strawn JR, Keck PE Jr, and Caroff SN, "Neuroleptic Malignant Syndrome," Am J Psychiatry , 2007, 164(6):870-6. [PubMed 17541044 ] Watts RL, “The Role of Dopamine Agonists in Early Parkinson's Disease,” Neurology , 1997, 49(1 Suppl 1):34-48. Weintraub D, Siderowf AD, Potenza MN, et al, “Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease,” Arch Neurol , 2006, 63(7):969-73. [PubMed 16831966 ] Topic 9164 Version 48.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [0504-58.240.98.179-8913731101-S244013.14]